Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 277-403-5 | CAS number: 73378-63-9
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From August 29, 2016 to December 13, 2016
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- other company data
- Title:
- Unnamed
- Year:
- 2 016
- Report date:
- 2016
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- yes
Test material
- Reference substance name:
- Copper, [29H,31H-phthalocyaninato(2-)-N29,N30,N31,N32]-, chlorosulfonyl derivs., reaction products with 2-[(4-aminophenyl)amino]-5-nitrobenzenesulfonic acid, sodium salts
- EC Number:
- 277-403-5
- EC Name:
- Copper, [29H,31H-phthalocyaninato(2-)-N29,N30,N31,N32]-, chlorosulfonyl derivs., reaction products with 2-[(4-aminophenyl)amino]-5-nitrobenzenesulfonic acid, sodium salts
- Cas Number:
- 73378-63-9
- Molecular formula:
- C32H16CuN8.C12H11N3O5S.Na
- IUPAC Name:
- Copper, [29H,31H-phthalocyaninato(2-)-N29,N30,N31,N32]-, chlorosulfonyl derivs., reaction products with 2-[(4-aminophenyl)amino]-5-nitrobenzenesulfonic acid, sodium salts
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- - Name of test material (as cited in study report): Everlan SL53
- Substance type: Powder
- Composition of test material, percentage of components: 73.75 %
- Lot/batch No.: 4508
- Storage condition of test material: Ambient
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- - Source: BioLASCO Taiwan Co., Ltd (Taipei, Taiwan)
- Age at study initiation: about 8 week old
- Housing: two animals per cage
- Water: ad libitum
- Acclimation period: at least 7 days
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 55 ± 15%
- Photoperiod (hrs dark / hrs light): 12-hrs dark / 12-hrs light cycle
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Doses:
- 2000 mg/kg B.W.
- No. of animals per sex per dose:
- three
Results and discussion
Effect levels
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
Any other information on results incl. tables
Table 1. Body weight of the rats in the study period
Animal I.D. |
Dosing volume (mL) |
Body weight (g) |
Weight changes (g) |
|
Day 1 |
Day 14 |
|||
Group 1 |
||||
01F |
2.2 |
217.4 |
247.3 |
+29.9 |
02F |
2.2 |
213.3 |
244.5 |
+31.2 |
03F |
2.2 |
211.9 |
256.8 |
+44.9 |
Group 2 |
||||
04F |
2.2 |
214.8 |
249.5 |
+34.7 |
05F |
2.2 |
215.2 |
244.3 |
+29.1 |
06F |
2.2 |
218.8 |
242.4 |
+23.6 |
Table 2. Clinical observation of the rats
Animal I.D. |
Clinical sign observation |
||||||||||||||
30 mins |
4 hrs |
D2 |
D3 |
D4 |
D5 |
D6 |
D7 |
D8 |
D9 |
D10 |
D11 |
D12 |
D13 |
D14 |
|
Group 1 |
|||||||||||||||
01F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
02F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
03F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
Group2 |
|||||||||||||||
04F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
05F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
06F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N: Normal.
D2-D14: Day 2-Day 14 in the study period.
Table 3. Results of gross necropsy examination
Animal I.D. |
Dose |
Gross lesion |
Group 1 |
||
01F |
2,000 mg/kg B.W. |
No significant lesion founded |
02F |
No significant lesion founded |
|
03F |
No significant lesion founded |
|
Group 2 |
||
04F |
2,000 mg/kg B.W. |
No significant lesion founded |
05F |
No significant lesion founded |
|
06F |
No significant lesion founded |
|
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- According to OECD 423 test method, the LD50 of Everlan SL53 was greater than 2000 mg/kg B.W.. Therefore, Everlan SL53 was Category 5 based on GHS criteria, and it is not classified under CLP.
- Executive summary:
This test using the procedures outlined in the SuperLab for M62-151100157001EN which is based on the SOP (SOPP-341) for the OECD 423 and OECD 423 (OECD, 2001). A total of 6 female Sprague-Dawley rats were orally dosed with Everlan SL53 in three animals each group, at 2000 mg/kg b.w. for both Group 1 and Group 2 in limit test. All animals tolerated the test article well with increasing body weights and no mortality or gross lesions findings reported. In absence of mortality or other significant clinical signs of toxicity, LD50 of Everlan SL53 was greater than 2,000 mg/kg.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
